Maher Ghawji, MD
Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1134181910
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 713 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 713 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$2K
- Abbott$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$728
- AbbVie$597
- plus $5K from 47 others
What the payments were for
- Food & beverage$12,885100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$322
- EVENITY$269
- FARXIGA$124
- FreeStyle Libre Pro$117
- FreeStyle Libre$111
How this compares
$12,927 in reported general payments places this provider in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 588 | $812,003 |
| MounjaroTirzepatide | 309 | $491,898 |
| TrulicityDulaglutide | 276 | $423,372 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 143 | $153,402 |
| JardianceEmpagliflozin | 95 | $124,151 |
| Tresiba Flextouch U-100Insulin Degludec | 135 | $121,069 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 75 | $103,421 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 78 | $102,142 |
| Tresiba Flextouch U-200Insulin Degludec | 68 | $95,398 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 14 | $90,741 |
| FarxigaDapagliflozin Propanediol | 52 | $68,889 |
| TymlosAbaloparatide | 26 | $66,239 |
| JanuviaSitagliptin Phosphate | 56 | $62,841 |
| Xigduo XrDapaglifloz Propaned/Metformin | 47 | $54,455 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $50,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $1,077 | $978,077647 claims |
| Novo NordiskOzempic, Novolog | $2,264 | $819,756616 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Tradjenta, Glyxambi | $728 | $301,062233 claims |
| MerckJanumet Xr, Januvia, Janumet | $413 | $266,362242 claims |
| NovartisSandostatin Lar Depot | $41 | $90,74114 claims |
| AstraZenecaFarxiga | $566 | $68,88952 claims |
| Radius Health, Inc.Tymlos | $45 | $66,23926 claims |
| AbbVieSynthroid | $597 | $38,523425 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $558 | $21,02118 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $12,2531,089 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Memphis
- Alan CohenMemphis$1.4M
- Shimon HararyMemphis$735K
- Samuel Dagogo-JackMemphis$407K
- Aidar GosmanovMemphis$138K
- Malini GuptaMemphis$91K
- Benjamin BrannickMemphis$84K
- Pedro VelasquezMemphis$21K
- Fariha SalmanMemphis$14K
- Yunna JiangMemphis$12K
- Rabia RehmanMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.